The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats

Neuroscience Letters

Volumn 499, Issue 1, 2011, Pages 24-27

  Kasai, Makiko ^a   Shioda, Katsutoshi ^a   Nisijima, Koichi ^a   Yoshino, Tatsuki ^a   Iwamura, Tatsunori ^b   Kato, Satoshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b MATSUYAMA UNIVERSITY   (Japan)

Author keywords

5 HT transporter; 5 HT2A receptor; Fluoxetine; Hyperthermia; MDMA; Mirtazapine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUOXETINE; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG EFFECT; HYPERTHERMIA; MALE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RECTUM TEMPERATURE;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DISEASE MODELS, ANIMAL; FEVER; FLUOXETINE; MALE; MIANSERIN; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN AGENTS;

EID: 79959293687     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.05.024     Document Type: Article

References (32)

1. Bankson M.G., Cunningham K.A. 3,4-methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interaction. J. Pharmacol. Exp. Ther. 2001, 297:846-852.
2. Blessing W.W., Seaman B., Pedersen N.P., Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J. Neurosci. 2003, 23:6385-6391.
3. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
4. Farré M., Abanades S., Roset P.N., Peiró A.M., Torrens M., O'Mathúna B., Segura M., de la Torre R. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J. Pharmacol. Exp. Ther. 2007, 323:954-962.
5. Fetter J.C. Mirtazapine for MDMA-induced depression. Am. J. Addiction 2005, 14:300-301.
6. Gillman P.K. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum. Psychopharmacol. Clin. Exp. 2006, 21:117-125.
7. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry 2006, 59:1046-1051.
8. Green A.R., O'Shea E., Saadat K.S., Elliott J.M., Colado M.I. Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br. J. Pharmacol. 2005, 146:306-312.
9. Hall A.P., Henry J.A. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 2006, 96:678-685.
10. Hjorth S. Hypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT. J. Neural. Trans. 1985, 61:131-135.
11. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm. 1997, 104:135-146.
12. Konqsamut S., Roehr J.E., Cai J., Hartman H.B., Weissensee P., Kerman L.L., Tanq L., Sandrasaqra A. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. J. Pharmacol. 1996, 317:417-423.
13. Krishnamoorthy S., Ma Z., Zhang G., Wei J., Auerbach S.B., Tao R. Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain. Basic Clin. Pharmacol. Toxicol. 2010, 107:830-841.
14. Leysen J.E., Janssen P.M., Mogens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 1994, 55(Suppl):5-12.
15. Lyles J., Cadet L. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Rev. 2003, 42:155-168.
16. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 2002, 135:170-180.
17. Millan M.J., Gobert J.M.R., Adhumeau-Auclair A., Cussac D., Newman-Tancredi A., Dekeyne A., Nicolas J.P., Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000, 12:1079-1095.
18. Montoya A.G., Sorrentino R., Lukas S.E., Price B.H. Long-term neuropsychiatric consequences of " ecstasy" (MDMA): a review. Harv. Rev. Psychiatry 2002, 10:212-220.
19. Nakayama K., Sakurai T., Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res. Bull. 2004, 63:237-241.
20. Nash J.F., Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 1991, 259:820-825.
21. Nisijima K., Yoshino T., Yui K., Katoh S. Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001, 890:23-31.
22. O'Connell M.T., Sarna G.S., Curzon G. Evidence for postsynaptic medication of the hypothermic effect of 5-HT1A receptor activation. Br. J. Pharmacol. 1992, 106:603-609.
23. O'Shea E., Esteban B., Camarero J., Green A.R., Colado M.I. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 2001, 40:65-74.
24. Parrott A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71:837-844.
25. Rudnick G., Wall S.C. The molecular mechanism of " ecstasy" [3,4-methylenedioxy-MAP (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:1817-1821.
26. Shioda K., Nisijima K., Yoshino T., Kato S. Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:633-640.
27. Shioda K., Nisijima K., Yoshino T., Kuboshima K., Iwamura T., Yui K., Kato S. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 2008, 29:1030-1036.
28. Shioda K., Nisijima K., Yoshino T., Kato S. Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci. Lett. 2010, 482:216-219.
29. Silins E., Copeland J., Dillon P. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust. N.Z.J. Psychiatry 2007, 41:649-655.
30. Wikström H.V., Mensonides-Harsema M.M., Cremers T.I., Moltzen E.K., Arnt J. Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J. Med. Chem. 2002, 45:3280-3285.
31. Vuori E., Henry J.A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P., Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003, 98:365-368.
32. Zhang G., Tao R. Enhanced responsivity of 5-HT2A receptors at warm ambient temperatures is responsible for the augmentation of the 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia. Neurosci. Lett. 2011, 490:68-71.